How big is the South & Central America Biologics Market?

The South & Central America Biologics Market is valued at US$ 16,517.2 Million in 2023, it is projected to reach US$ 54,534.7 Million by 2031.

What is the CAGR for South & Central America Biologics Market by (2023 - 2031)?

As per our report South & Central America Biologics Market, the market size is valued at US$ 16,517.2 Million in 2023, projecting it to reach US$ 54,534.7 Million by 2031. This translates to a CAGR of approximately 16.1% during the forecast period.

What segments are covered in this report?

The South & Central America Biologics Market report typically cover these key segments- 产品（单克隆抗体、疫苗、重组激素/蛋白质、细胞和基因治疗等）应用（癌症、传染病、自身免疫性疾病等）来源（哺乳动物和微生物）

What is the historic period, base year, and forecast period taken for South & Central America Biologics Market?

The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America Biologics Market report: 2025-2031 2023 2021-2023

Who are the major players in South & Central America Biologics Market?

The South & Central America Biologics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include: AbbVie Inc ; Pfizer Inc ; Samsung Biologics Co Ltd ; ADMA Biologics, Inc. ; Wuxi Biologics Inc ; Catalent Inc ; AGC Biologics AS ; AstraZeneca Plc ; Amgen Inc ; Nitto Avecia ; Quality Assistance s.a.

Who should buy this report?

The South & Central America Biologics Market report is valuable for diverse stakeholders, including: Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns. Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies. Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry. Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies. Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market. Essentially, anyone involved in or considering involvement in the South & Central America Biologics Market value chain can benefit from the information contained in a comprehensive market report.

南美和中美生物制剂市场（主要地区、市场参与者、规模和份额）- 预测至 2031 年

2023 年，南美和中美生物制剂市场价值为 165.172 亿美元，预计到 2031 年将达到 545.347 亿美元；预计 2023 年至 2031 年的复合年增长率为 16.1%。

生物制剂地区基因和细胞疗法的进步推动南美和中美生物制剂市场的发展

基因和细胞疗法是生物制剂市场中最有前景和增长最快的领域之一。这些疗法有可能通过从基因或细胞水平解决疾病的根本原因而不是仅仅控制症状来治愈或显著缓解疾病。基因疗法涉及在患者细胞中引入或修改遗传物质以治疗或预防疾病。在治疗镰状细胞性贫血、肌营养不良症和某些遗传性失明等遗传疾病方面已经取得了重大进展。基因编辑技术（尤其是 CRISPR）的发展进一步提高了这些疗法的精准度和有效性，使其成为治疗此前无法治愈疾病的可行方案。细胞疗法，包括干细胞和 CAR-T（嵌合抗原受体 T 细胞）疗法，为多种疾病（包括某些癌症、自身免疫性疾病和组织再生）提供了创新疗法。尤其是 CAR-T 疗法，它利用患者的免疫细胞直接攻击癌细胞，彻底改变了血癌的治疗方法。基因和细胞疗法的复杂性和专业性为生物制剂制造商提供了高价值机遇。尽管面临生产、成本和监管审批方面的挑战，但突破性、挽救生命的疗法的潜力使其成为一个不断扩张且利润丰厚的细分市场。

南美和中美生物制剂市场概览

南美和中美生物制剂市场分为巴西、阿根廷以及南美和中美其他地区。遗传病患病率的上升、个性化医疗和生物制剂需求的不断增长，以及随着技术进步而涌现的产品数量激增，预计将推动该地区市场的增长。根据2021年发表的一项题为《巴西医学遗传学劳动力：从业人员、服务和疾病分布》的研究，2019-2020年约有53,746例活产婴儿被诊断患有罕见遗传病，其中498例患有遗传性癌症综合征。2022年5月发表的一项题为《巴西罕见基因组计划》的研究指出，巴西有1320万人患有罕见病。遗传病和慢性病患病率的上升是推动巴西生物制剂市场增长的主要因素。巴西拥有强大的国内药品生产能力，这为其贸易活动提供了支持，并为其GDP做出了显著贡献。根据美国商务部的数据，Hypermarcas 和 EMS Sigma Pharma 等国内公司约占巴西制药公司总数的 80%。如此优越的制药和生物制药行业支持了巴西生物制剂市场的增长。贝伐单抗、西妥昔单抗和帕尼单抗是巴西批准用于治疗转移性结直肠癌 (mCRC) 的三种主要单克隆抗体。

南美和中美生物制剂市场收入及预测至 2031 年（百万美元）

南美和中美生物制剂市场细分

南美和中美生物制剂市场分为产品、应用、来源、制造和国家。

根据产品，南美和中美生物制剂市场细分为单克隆抗体、疫苗、重组激素/蛋白质、细胞和基因治疗等。单克隆抗体细分市场在 2023 年占据最大市场份额。

按应用分类，南美和中美生物制剂市场分为癌症、传染病、自身免疫性疾病等。2023 年，癌症细分市场占据最大市场份额。

按来源分类，南美和中美生物制剂市场分为哺乳动物和微生物。2023 年，哺乳动物细分市场占据较大市场份额。

按制造分类，南美和中美生物制剂市场分为外包和内部制造。2023 年，外包细分市场占据较大市场份额。

按国家分类，南美和中美生物制剂市场分为巴西、阿根廷和南美和中美其他地区。2023 年，巴西占据了南美和中美生物制剂市场的主导地位。

艾伯维公司；辉瑞公司；三星生物制剂有限公司； ADMA Biologics, Inc.；无锡生物技术有限公司；Catalent Inc；AGC Biologics AS；阿斯利康公司；安进公司；Nitto Avecia；以及 Quality Assistance sa 是南美和中美生物制剂市场的一些领先公司。

South & Central America Biologics Strategic Insights

Strategic insights for South & Central America Biologics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/south-and-central-america-biologics-market-strategic-framework.webp

Get more information on this report

South & Central America Biologics Report Scope

Report Attribute	Details
Market size in 2023	US$ 16,517.2 Million
Market Size by 2031	US$ 54,534.7 Million
Global CAGR (2023 - 2031)	16.1%
Historical Data	2025-2031
Forecast period	2021-2023
Segments Covered	By 产品（单克隆抗体、疫苗、重组激素/蛋白质、细胞和基因治疗等） By 应用（癌症、传染病、自身免疫性疾病等） By 来源（哺乳动物和微生物） By 制造（外包和内部）
Regions and Countries Covered	南美洲和中美洲（巴西、阿根廷、南美洲和中美洲其他地区）南美洲和中美洲（巴西、阿根廷、南美洲和中美洲其他地区）
Market leaders and key company profiles	AbbVie Inc Pfizer Inc Samsung Biologics Co Ltd ADMA Biologics, Inc. Wuxi Biologics Inc Catalent Inc AGC Biologics AS AstraZeneca Plc Amgen Inc Nitto Avecia

Get more information on this report

South & Central America Biologics Regional Insights

The regional scope of South & Central America Biologics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.